Slides
Page 1
Business Results First Nine Months of the Fiscal Year Ending March 31, 2026 Sysmex Corporation February 12, 2026
Page 2
Disclaimer ・ This material contains forward - looking statements about the Sysmex Group. These forward - looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward - looking statements. ・ The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained. ・ The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.
Page 3
Index 3 Business Results, First Nine Months of the Fiscal Year Ending March 31, 2026 1. (Appendix) 2. Growth Strategy Progress 3. Executive Summary 4 . Financial Forecast for the Fiscal Year Ending March 31, 2026 5 . Looking Ahead to the Next Mid - Term Management Plan
Page 4
Executive Summary 1.
Page 5
5 5 - Executive Summary Results for the First Nine Months of the Fiscal Year Ending March 31, 2026 ⚫ Despite favorable results in the Americas and EMEA, sales and profits were down, due to on going changes in the Chinese market environment. Year on year, net sales were down 1.6%, operating profit was down 27.7%, and profit attributable to owners of the parent was down 20.9%. Net sales - Sales grew in the Americas and EMEA, mainly on the hematology and urinalysis fields. - In China, the effects of government - driven healthcare cost control policies persisted. Sales in China declined 19.0% year on year on a local currency basis due to the principle of minimal necessity (restrictions on set tests) and Inventory adjustments by distributors. Operating profit - Although SG&A expenses optimized, operating profit declined, affected, additional U.S. tariffs, and a decrease in gross profit on lower sales. Profit attributable to owners of the parent - In line with expectations (progress rate: 74.9%), reflecting foreign exchange impacts and tax effects associated with the liquidation of an affiliated company according to the Life science Business - Pivot.
Page 6
6 6 Executive Summary Financial Forecast for the Fiscal Year Ending March 31, 2026 ⚫ We have revised downwards our forecast for net sales to ¥500.0 billion ( - ¥10.0 billion), and for operating profit to ¥62.0 billion ( - ¥14.0 billion). Note : Figures in parentheses indicate the difference from the forecast disclosed in November. Net sales - Revised downward, reflecting the greater - than - expected impact of market environment changes in China, the revision of the medical robotics business plan in Japan, and conditions in other regions. Operating profit - Revised downward, reflecting lower gross profit resulting from reduced sales, as well as a deterioration in the cost ratio driven by factors such as product mix.
Page 7
Business Results, First Nine Months of the Fiscal Year Ending March 31, 2026 2.
Page 8
8 8 First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Results Ratio Results Ratio Net sales 361.1 100% 366.8 100% 98.4% Cost of sales 173.5 48.0% 168.0 45.8% 103.3% SG&A expenses 120.2 33.3% 109.9 30.0% 109.3% R&D expenses 20.4 5.7% 22.5 6.1% 90.7% Other income (expenses) 1.6 0.5% 1.0 0.3% 159.8% Operating profit 48.6 13.5% 67.3 18.4% 72.3% Profit attributable to owners of the parent 33.6 9.3 % 42.6 11.6 % 79.1% Financial Highlights (Year on Year) ⚫ Net sales: Sales decreased, mainly due to the impact of changes in the market environment in China. ⚫ Operating profit: Profit declined, reflecting lower gross profit resulting from the decrease in sales, as well as the impact of additional U.S. tariffs. ✓ Forex impact: Sales: - ¥0.09 billion, SG&A expenses: +¥0.50 billion, operating profit: - ¥2.68 billion ✓ At the rates prevailing one year earlier: Sales down 1.5%, SG&A expenses up 8.9%, operating profit down 23.8% ⚫ Profit attributable to owners of the parent: Despite profit fell 20.9%, results were generally in line with the plan (progress rate: 74.9%) ✓ Foreign exchange gain (loss): ¥2.01 billion (+¥4.41 billion year on year) ✓ Tax adjustment effects related to the liquidation of affiliated company according to the Life science Business - Pivot: +¥2.58 billion (Billions of yen) 258.9 298.7 326.5 366.8 361.1 49.3 54.3 54.2 67.3 48.6 32.5 35.1 34.4 42.6 33.6 2022 2023 2024 2025 2026 Net sales Operating profit Profit attributable to owners of the parent (Billions of yen) First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 1US D ¥148.7 ¥152.6 1EUR ¥171.8 ¥164.8 1CNY ¥20.8 ¥21.2 (First nine months of years to March 31)
Page 9
9 9 Breakdown of Net Sales (by Business and Field) First nine months of fiscal year ending March 31, 2026 YoY (Previous period = 100%) Results Ratio Yen basis Excluding FX impact Net sales 361.1 100.0% 98.4% 98.5% Hematology 216.9 60.1% 98.1% 98.2% FCM 2.9 0.8% 123.5% 122.3% Urinalysis 32.0 8.9% 106.0% 106.5% Hemostasis 53.7 14.9% 93.9% 94.2% Immunochemistry 15.9 4.4% 86.9% 88.0% Clinical chemistry 2.1 0.6% 80.4% 81.6% Life science 17.0 4.7% 106.9% 103.8% Others 18.0 5.0% 116.0% 113.9% Diagnostics business 358.8 99.4% 98.7% 98.7% Medical robotics business 2.3 0.6% 70.3% 70.3% (Billions of yen) Sales by Business and Field Hemostasis Urinalysis Immuno - chemistry Others LS FX impact Hematology FCM Medical robotics - ¥5.6 billion 2025 2026 (Billions of yen) (First nine months of years to March 31) 366.8 - 3.89 0.53 1.96 - 3.31 - 2.19 0.60 1.68 - 0.97 - 0.09 361.1
Page 10
10 10 2025 Instruments Reagents Services Others FX impact 2026 Breakdown of Net Sales (by Destination and Product Type) Americas • Favorable performance in North America continued following 1H, strong growth in Central and Latin America continued from Q2 onward, resulting in higher sales overall. In Q3 alone, sales grew 9.4% year on year. EMEA • Strong performance in hematology and urinalysis across major countries and Eastern Europe offset sales declines in the Middle East, resulting in higher sales overall. In Q3 alone, sales increased significantly by 12.6% year on year. China • Sales declined due to the expanding impact of healthcare cost control policies (including the principle of minimal necessity), as well as expanded inventory adjustments driven by deteriorating distributor finances and cautious purchasing behavior. AP • Despite the delay of large - scale tender projects in India, sales increased , supported by growth in other regions. Japan • Sales decreased due to a reaction to strong hematology instrument sales in the previous fiscal year, as well as the continued impact of special factors. Instruments 70.5 19.5 % 99.0% 98.5% Reagents 225.8 62.5 % 98.6% 98.7% Services 50.9 14.1% 100.8% 101.4% Others 13.8 3.8% 86.7% 85.7% Major Reasons for Changes by Destination Note: On a local currency basis First nine months of fiscal year ending March 31, 2026 YoY (Previous period = 100%) Results Ratio Yen basis Local currency basis Net sales 361.1 100.0% 98.4% 98.5% Americas 100.8 27.9% 104.6% 107.1% EMEA 114.9 31.8% 111.7% 107.0% China 65.5 18.2% 79.9% 81.0% AP 39.3 10.9% 102.6% 104.1% Japan 40.5 11.2% 85.8% - (Billions of yen) (Billions of yen) By Product Type (Billions of yen) * * * * * * *Year - on - year change on a yen basis, excluding the impact of exchange rate fluctuations Net sales were down, owing to the impact of performance in Japan and China, although sales rose firmly in the Americas, EMEA, and AP. By Destination (First nine months of years to March 31) (First nine months of years to March 31) 366.8 6.54 8.44 - 15.47 1.55 - 6.68 - 0.09 361.1 366.8 - 1.03 - 2.99 0.71 - 2.27 - 0.09 361.1 2025 Americas EMEA China AP Japan FX impact 2026
Page 11
11 11 Information by Destination (Americas) 248.2 266.4 284.2 321.8 339.5 139.6 144.2 151.4 134.6 149.3 144.9 154.2 159.7 175.8 188.4 533.2 565.0 595.4 632.3 677.2 2022 2023 2024 2025 2026 ⚫ Instruments ✓ Installations progressed steadily, with favorable performance in the hematology and urinalysis fields, as well as growth in the hemostasis field. ✓ In particular, installations in large - scale facilities advanced in the urinalysis field, and we anticipate further growth. ⚫ Reagents ✓ Reagent sales increased, reflecting steady performance in the hematology and urinalysis fields. ✓ Amyloid β test reagents continued to show solid performance (sales USD 6.1 million, up 24.9% year on year). ✓ In the hemostasis field, reagent sales are expected to increase going forward in line with higher instrument sales . Favorable performance in North America continued following 1H, strong growth in Central and Latin America continued from Q2 onward, resulting in higher sales overall. In Q3 alone, sales grew 9.4% year on year. (First nine months of years to March 31) Instruments Services, others (Million USD) First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 677.2 632.3 107.1% 104.6% Instruments 149.3 134.6 110.9% 108.4% Reagents 339.5 321.8 105.5% 103.0% Services, others 188.4 175.8 107.1% 104.6% Sales (Million USD) Reagents
Page 12
12 12 Information by Destination (EMEA) ⚫ Instruments ✓ Supported by the effects of the direct sales structure, the hematology and urinalysis fields performed strongly in Italy. ✓ XR - Series sales grew in countries such as the Czech Republic and Germany. ✓ In the hemostasis field, we won major tenders not only in Germany but also in Hungary and the Czech Republic, which are expected to contribute to future sales. ⚫ Reagents ✓ Despite sales declines in Turkey and Saudi Arabia, performance in key countries remained solid, resulting in growth across all Business fields. ✓ In the hemostasis field, reagent sales increased in countries such as Germany and Egypt, in line with the expansion of the installed instrument base. 312.1 316.5 352.0 390.2 412.7 138.4 151.3 141.8 136.7 154.3 88.8 92.1 92.9 97.2 100.9 539.6 560.1 586.8 624.1 667.9 2022 2023 2024 2025 2026 Sales increased due to s trong performance in hematology and urinalysis across major countries and Eastern Europe, resulting in higher sales overall. In Q3 alone, sales increased significantly by 12.6% year on year. First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 667.9 624.1 107.0% 111.7% Instruments 154.3 136.7 112.9% 118.1% Reagents 412.7 390.2 105.8% 110.3% Services, others 100.9 97.2 103.8% 108.4% (Million EUR) Sales (Million EUR) (First nine months of years to March 31) Note: Sales in Russia have been excluded, including for past years. Instruments Reagents Services, others
Page 13
13 13 Information by Destination (China) ⚫ Instruments ✓ Sales declined due to distributor inventory adjustments and other factors. ✓ Sales in the hemostasis field increased, with steady performance continuing from the second half of the previous fiscal year, supported by the impact of knockdown local production. ⚫ Reagents ✓ Due to the expanded impact of the principle of minimal necessity, the decline in the number of tests — particularly in the hemostasis field — had a significant impact. ✓ There was no significant difference in the trend of hematology test volumes. Sales declined due to the expanding impact of government - driven policies to control healthcare costs (principle of minimal necessity), as well as inventory adjustments associated with changes to primary distributors. 2,496 2,430 2,714 2,920 2,444 767 484 496 458 381 377 396 457 509 324 3,641 3,311 3,668 3,888 3,150 2022 2023 2024 2025 2026 -100% -50% 0% 50% 2023 Apr. 2024 Apr. 2025 Apr. ■ Hematology test volume trends in China (Sysmex estimate) * Average number of tests per unit compared to the April 2019 – March 2020 average 2025 Dec. First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 3,150.7 3,888.6 81.0% 79.9% Instruments 381.8 458.9 83.2% 82.4% Reagents 2,444.3 2,920.4 83.7% 82.4% Services, others 324.5 509.2 63.7% 63.1% Sales ( Million CNY) (Million CNY) (First six months of years to March 31) Instruments Services, others Reagents
Page 14
14 14 ‐ Outlook for China We expect the year - on - year decline to be most pronounced in Q4. From next fiscal year onward, the pace of decline should gradually ease, with performance remaining at a broadly flat level in 2H. Current situation • The impact of the principle of minimal necessity ‐ The reduction range has increased, particularly in the field of hemostasis. (e.g., D - Dimer) • The impact of the inventory adjustment driven by distributors - The impact is ongoing. Outlook Q4 • The impact of the principle of minimal necessity - The reduction range has increased, particularly in the field of hemostasis. • The impact of the inventory adjustment driven by distributors - The reduction of instrument sales is within the expected range. - The sales of reagents and consumables decreased more than anticipated Next fiscal year • 1H : continue to be negatively impacted year - on - year basis. 2H: expected to remain at broadly flat level 0 - 4.9% - 24.9% - 21.1% 2026.3 Q1 2026.3 Q2 2026.3 Q3 2026.3 Q4 2027.3 上期 2027.3 下期 代理店在庫調整 必要最小限の原則 その他（VBP、競合など） 全体の影響 On a local currency basis, down 25 – 30% (Percentage points) 2027.3 1H 2027.3 2H Distributor inventory adjustments Other (VBP, competition, etc.) Organic growth + portfolio expansion, etc. Principle of minimum necessity Overall impact Illustration of the Impact of Changes in the China Market Environment on YoY Performance by Quarter Hospitals Outpatients Number Change (VS. 2023) Patients (100 million people) Growth rate (VS. 2023) Tier 3 4,111 +256 28.7 9.1% Tier 2 12,294 ＋ 348 12.2 0% Tier 1 13,287 ＋ 35 2.5 0% Changes in the number of hospitals and patients in 2024
Page 15
15 15 Information by Destination (AP) Despite the delay of large - scale tenders in India, sales increased, supported by growth in other countries. 14.6 18.8 22.1 25.9 27.8 4.9 5.9 7.3 8.1 7.4 1.8 2.2 3.8 4.2 4.0 21.3 27.0 33.2 38.3 39.3 2022 2023 2024 2025 2026 (1.6) (2.2) * * (3.3) Diagnostics business ⚫ Instruments ✓ Sales declined due to lower sales in Indonesia, as well as the deferral of large tenders in India and other countries. ✓ A significant growth is expected driven by acquisition of large - scale tenders scheduled for Q4. ⚫ Reagents ✓ In addition to significant growth in the hemostasis field in Malaysia, sales increased supported by favorable performance in the hematology, urinalysis, and immunochemistry fields. Medical robotics business ✓ Total cumulative installations: four units. ✓ The number of surgeries continues to increase steadily, with more than 150 procedures performed in Singapore and Malaysia. First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Yen basis Net sales 39.3 38.3 102.6% (104.1%) Diagnostics business 39.2 38.3 102.4% Instruments 7.4 8.1 91.1% Reagents 27.8 25.9 107.6% Services, others 3.9 4.2 92.5% Medical robotics business 0.1 0.03 336.1% (Billions of yen) Reagents Instruments Services, others Note: Figures in parentheses exclude the impact of exchange rate fluctuations) Sales (Billion JPY) * ( ) indicate sales in Russia ＊ Sales in Russia excluded Sales in Russia included (First nine months of years to March 31)
Page 16
16 16 Diagnostics business ⚫ Instruments ✓ Instrument sales declined in reaction to strong performance in the hematology field in the previous fiscal year. ✓ We launched new products, including the CN - 700 in the hemostasis field and the HISCL - 5000 mid - scale change in the immunochemistry field ⚫ Reagents ✓ Sales declined due to special factors in Q1, as well as to a decrease in COVID - 19 testing. ✓ We launched multiple immunochemistry reagents, which we expect to contribute to future sales. Medical robotics business ✓ Although new installations declined year on year due to continued weak capital investment by hospitals, the cumulative installed base increased to 96 units in Japan (100 units globally). ✓ A total of ten units have been installed year to date in Japan (11 units globally). Information by Destination (Japan) Sales decreased due to a reaction to strong hematology instrument sales in the previous fiscal year, as well as the continued impact of special factors. 26.5 29.3 27.7 28.1 25.6 5.6 5.7 6.5 8.5 5.5 6.3 6.9 7.0 7.2 7.0 0.7 1.7 2.0 3.2 2.1 39.2 43.7 43.3 47.1 40.5 2022 2023 2024 2025 2026 First nine months of fiscal year ending March 31, 2026 First nine months of fiscal year ended March 31, 2025 YoY (Previous period = 100%) Yen basis Net sales 40.5 47.1 85.8% Diagnostics business 38.3 43.9 87.2% Instruments 5.5 8.5 65.6% Reagents 25.6 28.1 91.1% Services, others 7.0 7.2 97.7% Medical robotics business 2.1 3.2 67.4% Sales (Billion JPY) (Billions of yen) Medical robotics business Reagents Instruments Services, others (First nine months of years to March 31)
Page 17
17 17 2025.3 3Q 売上変動による粗利変動 原価率の変動 販管費の増加 償却費の増加 研究開発費の減少 その他営業損益の変動 為替の影響 2026.3 3Q Breakdown of Operating Profit (Year on Year) Operating profit (Billions of yen) - ¥18.6 billion 2025 2026 Higher SG&A expense Fluctuation in gross profit due to changes in net sales Change in the cost of sales ratio ⚫ Fluctuation in gross profit due to changes in net sales: - ¥3.03 billion ⚫ Impact of change in the cost of sales ratio: - ¥5.95 billion (1.6pt deterioration) ✓ Positive factor: Improved logistics costs, 0.1 pt ✓ Negative factors: Impact of product mix, 0.5 pt; Q1 inventory revaluations, 0.5pt, deterioration of service costs, 0.5pt, tariff impact, 0.3 pt ⚫ Higher SG&A expenses: - ¥7.38 billion ✓ Labor costs rose approx. ¥3.1 billion, due to personnel increases owing to expansion of the direct sales area, as well as higher unit costs. ✓ Other costs rose approx. ¥2.5 billion in line with an increase in scale and sales promotion activities. ⚫ Higher depreciation and amortization: - ¥2.35 billion ⚫ Lower R&D expenses: + ¥2.09 billion ✓ While investment in product development continues, total R&D expenses declined due to prioritization and narrowing of research themes. ⚫ Change in other operating expenses: ¥0.62 billion Note: Figures and comments below exclude the impact of exchange rates. ⚫ FX impact: - ¥2.68 billion 67.3 Increase in depreciation and amortization FX impact Lower R&D expenses Change in other operating expenses 48.6 - 3.03 - 5.95 - 7.38 - 2.35 2.09 0.62 - 2.68 (First nine months of years to March 31)
Page 18
Growth Strategy Progress 3. Reinforcement of Existing Businesses, Emerging Market Strategies, Expansion of New Businesses
Page 19
19 19 Three Growth Strategies: Reinforcement of Existing Businesses (Hemostasis Field) EMEA: Winning of large tenders in Germany and other countries Key countries with major new tender wins ⚫ Accelerate market expansion by leveraging brand strength CN - 9000 automated hemostasis solution CN - Series automated blood coagulation analyzer ⚫ Bolster our presence in the high - end market ✓ Rollout of the touch - free concept in the hemostasis field North America: Launched the CN - 9000 Japan: Launched the CN - 700 ✓ Compactly incorporate the performance of higher - end models ✓ Consider introduction in emerging markets CN - 700 automated blood coagulation analyzer ⚫ Expand our competitive advantage in mid - and low - end markets We are leveraging our strong foundation in hematology and the launch of new products to expand the value we deliver, driving higher customer satisfaction and accelerated growth.
Page 20
20 20 Three Growth Strategies: Reinforcement of Existing Businesses (Immunochemistry Field) We aim to increase growth by enhancing our presence and market penetration in Alzheimer’s disease testing. ⚫ Enhance market leadership through early market entry Began sales collaboration with Fujirebio HD ✓ Fujirebio HD’s extensive product lineup ✓ Sysmex’s global sales network ✓ Stronger collaboration with KOLs and participation in development of guidelines Target countries/areas: Begin with Brazil, Central and Latin America, the Middle East, and Asia In addition to rolling out the HISCL series in advanced markets, we are pursuing global expansion. ⚫ Presentation of MTBR - tau243 at international conferences ✓ World’s first presentation of an immunoassay using blood samples ✓ Strong expectations from drug discovery partners developing tau disease - modifying therapies In addition to anti - amyloid disease - modifying drugs, we are advancing the development of blood tests in anticipation of the arrival of anti - tau disease therapeutics.
Page 21
21 21 Three Growth Strategies: Emerging Market Strategy 109 128 99 156 181 197 2024 2025 2026 2,906 3,720 3,826 4,129 5,122 6,590 2024 2025 2026 META* * META : Middle East, Turkey, and Africa 22.2 25.7 27.0 30 32 43 2024 2025 2026 Brazil India (Million INR) (Million USD) (Million EUR) Q3 Q3 Q3 Full year Full year Full year Leverage our competitive advantage in emerging markets ⚫ Brazil: Long - standing trust grounded in high - customer satisfaction ✓ Successfully retained business at a large commercial lab in Brazil, overcoming competitors’ low - price strategies. Secured multiple - system installations for the XR - Series ⚫ Malaysia: Proposing solutions to laboratory - wide challenges beyond instrument replacement ✓ Our solutions were adopted by a reference laboratory positioned as a top - priority customer by competitors . XR - Series multiparameter automated hematology analyzer XQ - 320 multiparameter automated hematology analyzer for the Indian market (Fiscal years to March 31) (Fiscal years to March 31) (Fiscal years to March 31) ⚫ India: Advancing initiatives to address government procurement tenders ✓ Achieved Make in India Class I at a new production facility, and additionally obtained IVDD CE marking under European regulations.
Page 22
22 22 9,300 14,700 100 300 2024 2025 Q3 2026 55 86 96 4 2024 2025 Q3 2026 Three Growth Strategies: Expansion of New Businesses (Medical Robotics Business) hinotori TM units installed to date globally hinotori surgeries performed to date globally Total of approx. 15,000 surgeries 4,225 9,400 55 89 3 Total 100 units ■ Japan ■ Overseas ■ Japan ■ Overseas ✓ Japan: We are targeting further market penetration by introducing flexible sales schemes and benefiting from tailwinds, such as subsidies under programs aimed at enhancing functionality of university hospitals. ✓ AP: Against the backdrop of increasing case volumes in the expanding Asian market, we are advancing the selection of future entry countries and the development of market introduction frameworks. ✓ Europe: Assuming we receive regulatory approval, we will move forward with efforts to develop optimal market entry models. Accelerating market penetration and growth in case volumes, with cumulative installations surpassing 100 units (Years to March 31) (Years to March 31)
Page 23
Financial Forecast for the Fiscal Year Ending March 31, 2026 4.
Page 24
24 24 Revised Financial Forecast for the Fiscal Year Ending March 31, 2026 Q3 of Fiscal year ending March 31, 2026 (April – December) Fiscal year ending March 31, 2026 (April – March) Fiscal year ending March 31, 2026 (April – March) Results Ratio Vs. November Revised forecast November forecast Ratio Revised February Forecast Ratio YoY Vs. November forecast Net sales 361.1 100% 70.8% 510.0 100.0% 500.0 100.0% 98.3% - 10.0 Cost of sales 173.5 48.0% - 241.5 47.4% 244.0 48.8% 103.1% ＋ 2.5 SG&A expenses 120.2 33.3% - 163.5 32.1% 165.0 33.0% 109.4% ＋ 1.5 R&D expenses 20.4 5.7% - 30.0 5.9% 30.0 6.0% 95.4% － Other income (expenses) 1.6 0.5% - 1.0 - 1.0 0.2 ％ － － Operating profit 48.6 13.5% 64.0% 76.0 14.9% 62.0 12.4% 70.8% - 14.0 profit attributable to owners of the parent 33.6 9.3 ％ 74.9 ％ 45.0 8.8% 41.0 8.2% 76.4% - 4.0 Revision of Net Sales, Operating Profit, and Net Income Forecasts Downward Green indicates changes from previous forecast (announced in November 2025) Full year (Revised Nov. 2025) Full year (Revised Feb 2026) Q4 alone (Revised February 2026) 1 US D ¥148.5 ¥150.0 ¥154.0 1 EUR ¥171.5 ¥174.6 ¥183.0 1 CNY ¥20.8 ¥21.1 ¥22.0 ROE 8.5% Net Sales Operating profit US D ¥0.22 billion ¥0.03 billion EUR ¥0.18 billion ¥0.01 billion CNY * ¥0.09 billion ¥0.05 billion (Billions of yen) Planned investment Capital expenditure: ¥ 50.0 billion Depreciation and amortization: ¥ 45.0 billion ⚫ Assumed Exchange Rates *Per ¥0.1 change ⚫ Exchange Rate Sensitivity (Q4 alone)
Page 25
25 25 Revised Financial Forecast for the Fiscal Year Ending March 31, 2026 76.0 62.0 1.0 1.0 - 8.5 - 7.5 11月予想 売上減少に伴う粗利減 原価率悪化 利益貢献策の検討 円安影響 2月修正予想 Fluctuation in gross profit due to lower in net sales 510.0 500.0 5.7 - 8.6 - 3.0 - 1.6 - 1.5 - 1.0 11月予想 中国 日本 EMEA 米州 AP 円安影響 2月修正予想 Net sales Operating profit China Japan EMEA Americas AP FX impact November 2025 February 2026 FX impact November 2025 February 2026 • The impact of the principle of minimal necessity and distributor inventory adjustments in China was more extensive than we had anticipated. • In Japan, we revised plans for the medical robotics business in response to a deteriorating business environment. • Gross profit declined due to lower sales across regions. • The cost of sales ratio deteriorated due to product - mix etc. （ Billions of yen ） （ Billions of yen ） Deterioration in the cost of sales ratio Adjustments to SG&A expenses
Page 26
26 26 Quarterly Results and Forecast for the Fiscal Year Ending March 31, 2026 Q1 of fiscal year ending March 31, 2026 (April – June) Q2 of fiscal year ending March 31, 2026 (July – September) Q3 of fiscal year ending March 31, 2026 (October – December) Q4 of fiscal year ending March 31, 2026 (January – March) Results Ratio Results Ratio Results Ratio Forecast Ratio Net sales 105.7 100% 126.7 100% 128.6 100% 138.8 100% Cost of sales 51.2 48.5% 58.7 46.3% 63.5 49.4% 70.4 50.8% SG&A expenses 38.2 36.2% 39.5 31.2% 42.3 32.9% 44.7 32.3% R&D expenses 6.4 6.1% 6.7 5.4% 7.2 5.6% 9.5 6.9% Other income (expenses) 0.8 0.8% 0.6 0.5% 0.1 0.2% - 0.7 ー Operating profit 10.6 10.1% 22.3 17.6% 15.6 12.2% 13.3 9.6% profit attributable to owners of the parent 4.5 4.3 % 14.4 11.4% 14.8 11.5% 7.3 5.3% (Billions of yen)
Page 27
27 27 Cost of Sales Ratio by Quarter, and Outlook for the Fiscal Year Ending March 31, 2026 Q1 Q2 Q3 Q4 46.4% 45.4% 45.7% 48.4% Q1 (actual) Q2 (actual) Q3 (actual) Q4 (forecast) 48.5% 46.3% 49.4% 50.8% Cost of sales ratio, by quarter Fiscal year ended March 31, 2025 Cost of sales ratio by quarter (actual/forecast) Fiscal year ending March 31, 2026 Year on year ＋ 3.7pt +2.5 pt: Exchange rate effects, product mix, etc. +0.5 pt: Additional U.S. tariffs +0.7 pt: Changes in the China business environment vs. Q2 ＋ 3.1pt +2.0 pt: Exchange rate effects, product mix, etc. +0.3 pt: Additional U.S. tariffs +0.8 pt: Changes in the China business environment 49.0% Excluding the increase in reagent volume in Japan due to the effects of system transition Product mix (lower proportion of reagents) Increased impact of changes in the China business environment Product mix (lower proportion of reagents) Expanded impact of changes in the China business environment Additional U.S. tariffs Factors that may continue to have an impact Temporary factors/factors with potential for improvement
Page 28
28 28 Reference: Financial Forecast for the Fiscal Year Ending March 31, 2026 (Sales by Business, Field, and Destination) Sales by destination Fy03/ 202 6 YoY (Previous period = 100%) Hematology 299.5 98.8% FCM 5.0 137.4% Urinalysis 46.5 113.9% Hemostasis 72.0 87.4% I mmunochemistry 21.5 83.1% C linical chemistry 3.0 82.6% Life science 24.5 114.9% Others 24.5 109.3% Diagnostics business 496.5 98.7% Medical robotics business 3.5 65.2% Total 500.0 98.3% Fy03/ 202 6 YoY (Previous period = 100%) Americas 139.0 106.0% EMEA 161.5 115.0% China 86.0 72.9% Asia Pacific 55.5 108.1% Japan 58.0 85.6% Sales by business and field （ Billions of yen ） （ Billions of yen ） Text in green indicates revisions.
Page 29
Looking Ahead to the Next Mid - Term Management Plan 5.
Page 30
30 30 Key Points of the Next Medium - Term Management Plan ⚫ Commit to sustaining growth in existing businesses － Global rollout of new flagship model with novel solution ⚫ Accelerate digital transformation leveraging Sysmex’s strengths － Challenge to develop solutions that enhance the quality of the healthcare journey and customer value. － Transform corporate efficiency and productivity to the next stage. ⚫ Manage the business with full consideration of geopolitical and economic security risks worldwide, including changes in the business environment in China etc. ⚫ Strengthen management of the business portfolio and product pipeline with a focus on group - wide profitability ⚫ Develop and acquire next - generation talent who will lead the next stage of growth ⚫ Improve capital efficiency and enhance shareholder returns, including share buyback
Page 31
(Appendix)
Page 32
32 32 Highlights (October 2025 to January 2026) • Launch of CN - 9000 Automated Hemostasis Solution for Large - Scale Laboratories in North America (Americas) • Introduction of Compact Model to the CN - Series: Launch of the CN - 700 Automated Blood Coagulation Analyzer (Japan) • Launch of HISCL - 5000 Fully Automated Immunoassay System (Mid - Scale Change) (Japan) • Launch of the HISCL PCT Reagent for Measuring Procalcitonin, a Biomarker Used in Sepsis Testing (Japan) Diagnostics Business Sustainability • Sysmex Selected for CDP 2025 “Climate Change” A List • Sysmex Obtains “Platinum Kurumin Plus,” the Highest Level of Certification under the “ Kurumin ” Program Provided by the Ministry of Health, Labour and Welfare, Based on the Act on Advancement of Measures to Support Raising Next - Generation Children • Sysmex Receives the Highest Rating of GOLD in the “Pride Index” for Its Efforts Related to Sexual and Gender Minorities, for the Fourth Consecutive Year Launched new products in multiple fields Strengthened the business foundation to enhance sustainable growth capabilities